Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

NCT01085201 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01085201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01085201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2010
Completion date
March 31, 2013
Enrollment
39 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease